Gmppb-mutant mice exhibit dystroglycanopathy symptoms that are rescued with GSK3β inhibition or AAV-mediated GMPPB gene replacement.
Two different treatments—a drug and gene therapy—both successfully corrected a rare inherited muscular dystrophy in mice.
Two therapeutic strategies — a drug that inhibits GSK3β and gene therapy using AAV vectors — both successfully treated a rare muscular dystrophy caused by GMPPB mutations in mice. This provides dual paths toward clinical development for this ultra-rare condition.
What the study was
- Study design
- Preclinical (mouse model, gene therapy)
- Population
- GMPPB-related dystroglycanopathy mouse model
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Nature Communications
Why it surfaced
Dual therapeutic rescue for rare dystroglycanopathy in Nat Commun. High unmet need but preclinical/animal model only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.